Literature DB >> 1712682

Expression of CD34 on human B cell precursors.

C Schmitt1, C J Eaves, P M Lansdorp.   

Abstract

CD34 is a 110-kD glycoprotein previously shown by a variety of monoclonal antibodies (MoAbs) to be expressed selectively on immature hematopoietic cells. However, more detailed characterization of CD34+ cells has been hampered by lack of anti-CD34 MoAbs that can be labelled directly with fluorochromes to facilitate subpopulation analysis by multi-parameter flow cytometry. We have recently isolated a murine anti-CD34 MoAb, designated as 8G12, that can be directly labelled with fluorochromes such as FITC. In this study, we have exploited this property of 8G12 to compare the reactivity of 8G12 and My10 with normal and leukaemic human marrow cells and to characterize normal early human B cell precursors by two- and three-colour immunofluorescence analysis. Comparison of three-colour staining profiles of normal bone marrow cells incubated with both 8G12 and MY10, and either anti-CD10 or anti-CD19 MoAb revealed the reactivity patterns of 8G12 and MY10 to be indistinguishable. This conclusion was confirmed by a similar comparative analysis of 8G12 and MY10 staining of blood and bone marrow cells from 4 patients with B lineage acute lymphoblastic leukaemia (ALL). Of interest, both 8G12 and MY10 detected a CD34+CD10+CD19- population in normal adult bone marrow. To determine whether a CD34+CD10+CD19- precursor population previously reported by others to exist in fetal liver could also be identified, CD10+CD16- marrow cells were first isolated by FACS and the sorted cells then re-analysed for expression of CD19 and CD34. These studies showed that all of the sorted CD10+ cells that expressed CD34 appeared to coexpress CD19. No CD34+CD10+CD19- cells were detected (at a sensitivity of less than or equal to 0.1%). Further studies will be required to determine whether a very minor population of CD34+CD10+CD19- cells may still be generated in the normal development of B cells in adult human marrow.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712682      PMCID: PMC1535701          DOI: 10.1111/j.1365-2249.1991.tb05699.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow.

Authors:  C I Civin; M L Banquerigo; L C Strauss; M R Loken
Journal:  Exp Hematol       Date:  1987-01       Impact factor: 3.084

2.  Specific binding and release of cells from beads using cleavable tetrameric antibody complexes.

Authors:  T E Thomas; H J Sutherland; P M Lansdorp
Journal:  J Immunol Methods       Date:  1989-06-21       Impact factor: 2.303

3.  Immunobiologic differences between normal and leukemic human B-cell precursors.

Authors:  F M Uckun; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies.

Authors:  L Lu; D Walker; H E Broxmeyer; R Hoffman; W Hu; E Walker
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

5.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.

Authors:  M R Loken; V O Shah; K L Dattilio; C I Civin
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

6.  Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia.

Authors:  R G Smith; R L Kitchens
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

7.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells.

Authors:  C I Civin; L C Strauss; C Brovall; M J Fackler; J F Schwartz; J H Shaper
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

8.  Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells.

Authors:  P Hokland; J Ritz; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

Authors:  C A Hurwitz; M R Loken; M L Graham; J E Karp; M J Borowitz; D J Pullen; C I Civin
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

10.  Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors.

Authors:  D H Ryan; C W Chapple; S A Kossover; A A Sandberg; H J Cohen
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

View more
  5 in total

1.  Transplantable hematopoietic stem cells in human fetal liver have a CD34(+) side population (SP)phenotype.

Authors:  N Uchida; T Fujisaki; A C Eaves; C J Eaves
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Establishment and characterization of a novel CD34-positive human myeloid leukemia cell line: MHH225 growing in serum-free culture.

Authors:  H T Hassan; E Petershofen; E Lux; C Fonatsch; G Heil; M Freund
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

3.  Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.

Authors:  Aneel Paulus; Kasyapa S Chitta; Paul K Wallace; Pooja P Advani; Sharoon Akhtar; Maja Kuranz-Blake; Sikander Ailawadhi; Asher A Chanan-Khan
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

4.  Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.

Authors:  P M Lansdorp; W Dragowska
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

5.  Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes.

Authors:  Uwe Platzbecker; Ekaterina Balaian; Maik Herbig; Angela Jacobi; Manja Wobus; Heike Weidner; Anna Mies; Martin Kräter; Oliver Otto; Christian Thiede; Marie-Theresa Weickert; Katharina S Götze; Martina Rauner; Lorenz C Hofbauer; Martin Bornhäuser; Jochen Guck; Marius Ader
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.